FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018404967> ?p ?o ?g. }

• W2018404967 endingPage "662" @default.
• W2018404967 startingPage "651" @default.
• W2018404967 abstract "High-linear energy transfer radiation offers superior biophysical properties over conventional radiotherapy and may have a great potential for treating radioresistant tumors, such as glioblastoma. However, very little pre-clinical data exists on the effects of high-LET radiation on glioblastoma cell lines and on the concomitant application of chemotherapy. This study investigates the in vitro effects of temozolomide in combination with low-energy protons and α particles. Cell survival, DNA damage and repair, and cell growth were examined in four human glioblastoma cell lines (LN18, T98G, U87 and U373) after treatment with either X rays, protons (LET 12.91 keV/μm), or α particles (LET 99.26 keV/μm) with or without concurrent temozolomide at clinically-relevant doses of 25 and 50 μM. The relative biological effectiveness at 10% survival (RBE10) increased as LET increased: 1.17 and 1.06 for protons, and 1.84 and 1.68 for α particles in the LN18 and U87 cell lines, respectively. Temozolomide administration increased cell killing in the O6-methylguanine DNA methyltransferase-methylated U87 and U373 cell lines. In contrast, temozolomide provided no therapeutic enhancement in the methylguanine DNA methyltransferase-unmethylated LN18 and T98G cell lines. In addition, the residual number of γ-H2AX foci at 24 h after treatment with radiation and concomitant temozolomide was found to be lower than or equal to that expected by DNA damage with either of the individual treatments. Kinetics of foci disappearance after X-ray and proton irradiation followed similar time courses; whereas, loss of γ-H2AX foci after α particle irradiation occurred at a slower rate than that by low-LET radiation (half-life 12.51–16.87 h). The combination of temozolomide with different radiation types causes additive rather than synergistic cytotoxicity. Nevertheless, particle therapy combined with chemotherapy may offer a promising alternative with the additional benefit of superior biophysical properties. It is also possible that new fractionation schedules could be designed to exploit the change in DNA repair kinetics when MGMT-methylated cells respond to high-LET radiation." @default.
• W2018404967 created "2016-06-24" @default.
• W2018404967 creator A5009792664 @default.
• W2018404967 creator A5050287039 @default.
• W2018404967 creator A5053648656 @default.
• W2018404967 creator A5055316161 @default.
• W2018404967 creator A5059681293 @default.
• W2018404967 creator A5062914081 @default.
• W2018404967 creator A5073323606 @default.
• W2018404967 date "2012-05-01" @default.
• W2018404967 modified "2023-09-26" @default.
• W2018404967 title "<i>In Vitro</i>Evaluation of Combined Temozolomide and Radiotherapy Using X Rays and High-Linear Energy Transfer Radiation for Glioblastoma" @default.
• W2018404967 cites W1847687345 @default.
• W2018404967 cites W1965905617 @default.
• W2018404967 cites W1968601707 @default.
• W2018404967 cites W1978509832 @default.
• W2018404967 cites W1982381330 @default.
• W2018404967 cites W1989983799 @default.
• W2018404967 cites W2000388819 @default.
• W2018404967 cites W2001404230 @default.
• W2018404967 cites W2002664587 @default.
• W2018404967 cites W2009246149 @default.
• W2018404967 cites W2011006143 @default.
• W2018404967 cites W2015782123 @default.
• W2018404967 cites W2018371543 @default.
• W2018404967 cites W2029445057 @default.
• W2018404967 cites W2034200080 @default.
• W2018404967 cites W2040881358 @default.
• W2018404967 cites W2047258681 @default.
• W2018404967 cites W2053311488 @default.
• W2018404967 cites W2053700561 @default.
• W2018404967 cites W2066192654 @default.
• W2018404967 cites W2068220280 @default.
• W2018404967 cites W2069150999 @default.
• W2018404967 cites W2076173823 @default.
• W2018404967 cites W2076406635 @default.
• W2018404967 cites W2077922140 @default.
• W2018404967 cites W2088925558 @default.
• W2018404967 cites W2095148496 @default.
• W2018404967 cites W2095436114 @default.
• W2018404967 cites W2096287682 @default.
• W2018404967 cites W2104900835 @default.
• W2018404967 cites W2105100844 @default.
• W2018404967 cites W2107073756 @default.
• W2018404967 cites W2114012083 @default.
• W2018404967 cites W2132015861 @default.
• W2018404967 cites W2141510524 @default.
• W2018404967 cites W2154451644 @default.
• W2018404967 cites W2158681922 @default.
• W2018404967 cites W2161227192 @default.
• W2018404967 cites W2162041180 @default.
• W2018404967 cites W2167713837 @default.
• W2018404967 cites W2168960151 @default.
• W2018404967 cites W2171670603 @default.
• W2018404967 doi "https://doi.org/10.1667/rr2803.1" @default.
• W2018404967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22468703" @default.
• W2018404967 hasPublicationYear "2012" @default.
• W2018404967 type Work @default.
• W2018404967 sameAs 2018404967 @default.
• W2018404967 citedByCount "31" @default.
• W2018404967 countsByYear W20184049672012 @default.
• W2018404967 countsByYear W20184049672013 @default.
• W2018404967 countsByYear W20184049672014 @default.
• W2018404967 countsByYear W20184049672015 @default.
• W2018404967 countsByYear W20184049672016 @default.
• W2018404967 countsByYear W20184049672017 @default.
• W2018404967 countsByYear W20184049672018 @default.
• W2018404967 countsByYear W20184049672019 @default.
• W2018404967 countsByYear W20184049672020 @default.
• W2018404967 countsByYear W20184049672021 @default.
• W2018404967 countsByYear W20184049672022 @default.
• W2018404967 crossrefType "journal-article" @default.
• W2018404967 hasAuthorship W2018404967A5009792664 @default.
• W2018404967 hasAuthorship W2018404967A5050287039 @default.
• W2018404967 hasAuthorship W2018404967A5053648656 @default.
• W2018404967 hasAuthorship W2018404967A5055316161 @default.
• W2018404967 hasAuthorship W2018404967A5059681293 @default.
• W2018404967 hasAuthorship W2018404967A5062914081 @default.
• W2018404967 hasAuthorship W2018404967A5073323606 @default.
• W2018404967 hasConcept C111337013 @default.
• W2018404967 hasConcept C11928243 @default.
• W2018404967 hasConcept C121332964 @default.
• W2018404967 hasConcept C126322002 @default.
• W2018404967 hasConcept C128473837 @default.
• W2018404967 hasConcept C185544564 @default.
• W2018404967 hasConcept C185592680 @default.
• W2018404967 hasConcept C202751555 @default.
• W2018404967 hasConcept C2776194525 @default.
• W2018404967 hasConcept C2777389519 @default.
• W2018404967 hasConcept C2777658100 @default.
• W2018404967 hasConcept C2780964509 @default.
• W2018404967 hasConcept C2989005 @default.
• W2018404967 hasConcept C502942594 @default.
• W2018404967 hasConcept C509974204 @default.
• W2018404967 hasConcept C54355233 @default.
• W2018404967 hasConcept C55493867 @default.
• W2018404967 hasConcept C58962609 @default.
• W2018404967 hasConcept C71924100 @default.

• next